If you are an investor in sarepta and have a cost basis higher than 20 bucks you need to read this article. The author is not a basher, on the contrary an intelligent articulate experienced investor who logically presents her argument, which I must say is valid. The risk of sarepta not getting early approval is high. If you're long and strong then it shouldn't matter. But if you can't stand it if this stock sees a 8-15% pullback on disappointment over the aa, then you either need to protect position with puts or sell out. I recommend hedging with puts...better than losing your whole bankroll
Wow, talk about old news. A lot has happened (almost all of it good) since "DR Punjabi" wrote her article. She hasn't been heard from since...she's been very quiet on Twitter. I think she knows her May puts will expire worthless!
heh experienced, couldnt figure out options pricing. such bs. go all in shorts, i dare you. go listen to janet woodcock from the fda google search on "Making a Difference: Janet Woodcock, FDA" and your homework is to come back and tell me which drug she mentions coming across her desk but can't name. extra credit: why is hamburg meeting with DMD Hero and Jett Foundation tomorrow.
In the interview about current outstanding accomplishments in medicine Janet Woodcock mentions ' CHILDHOOD GENETIC diseases... Easy to assume - she means eteplirsen by SAREPTA
Sentiment: Strong Buy